BridgeBio Pharma secured credit assistance worth as much as $750 million to move forward with the company’s research and development efforts for the treatment of cancers and genetic diseases.

Organon announced the women’s health company is acquiring Finland-based Forendo Pharma, which focuses on intracrinology or sex steroid physiology in women.

AstraZeneca said on Nov. 1 the company will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.

Shares of Flexion Therapeutics soared in trading on Oct. 11 after Pacira Biosciences announced the acquisition of the Burlington, Massachusetts-based biopharmaceutical company for $427 million in cash.

Fresh out of the gates with $500 million in financing, neuroscience-focused Neumora Therapeutics forged a strategic partnership with Amgen to develop and commercialize assets owned by the pharma giant, targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.

After the historic approval of the company’s first-ever drug in January 2021, Aurinia Pharmaceuticals announced the acquisition of two pipeline assets that align with the Canadian biotech’s focus on autoimmune and kidney-related disease.

BioCryst Pharmaceuticals, a global biopharmaceutical company that focuses on developing treatments for rare diseases, canceled plans to hold a public offering to raise funds. 

Bayer AG is buying Vividion Therapeutics, a San Diego-based company that focuses on drug development using protein surface screening, in a $2 billion deal.

Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.

One day after Bristol Myers Squibb announced a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Artificial Intelligence (AI)-focused biopharma company Exscientia that could hit $1.2 billion.